Home' Australian Pharmacist : February 2013 Contents BUSINESS AND INDUSTRY NEWS
Australian Pharmacist February 2013 I ©Pharmaceutical Society of Australia Ltd. 75
At a time when the global pharmaceutical industry appears to be eating itself
with pharma companies merging with, acquiring or buying out competitors
the unheard of has happened.
On 1 January, on the 125th anniversary of
its founding, Abbott split itself into two
independent companies. While, Abbott
retains medical devices, diagnostics,
nutritionals and branded generic
pharmaceuticals, an independent new
biopharmaceutical company AbbVie was
launched by its leaders as they rang the
first opening bell of 2013 at the New York
Richard A. Gonzalez, Chairman of the
Board and AbbVie's Chief Executive Officer
said: 'Today AbbVie launches with an
outstanding portfolio, a solid pipeline and
enthusiastic people who will serve patients
and deliver growth. With those assets and a
relentless focus on innovation we intend to
create significant value for our shareholders.'
He said AbbVie has adopted a streamlined
and focused business model built on
a broad portfolio of market leading
medicines that will 'enable it to invest in
The portfolio includes growth brands and
durable performers, including: HUMIRA,
AndroGel, Lupron, Synagis, Creon, Synthroid,
Kaletra, Norvir and Zemplar.
and New Zealand
said that AbbVie's
with more than 20
mid- to late-stage
clinical programs, positions it to continue
developing therapies with strong clinical
performance, patient benefit and address
the economic issues of health care for
serious, chronic conditions.
'Australia is one of the top three
contributors for AbbVie in clinical research
outside of the United States, with nearly
5,500 patients enrolled in AbbVie-
supported clinical trials and studies at
approximately 350 sites across Australia and
New Zealand at any one time.
'This [launch] is an exciting day for AbbVie
and our nearly 200 colleagues in Australia.
We look forward to working together with
patients and healthcare partners to meet
the healthcare needs in Australia.'
Ms O'Doherty told Australian Pharmacist
that AbbVie wants to work collaboratively
with pharmacists and pharmacy because
it is playing an increasingly important role
'The company is really looking hard at how it
can work with pharmacy,' she said.
She said that in the immediate future the
company will focus on ensuring continuity
of supply. There will be some changes in
labelling and new branding
'The company's focus will be on research and
development, innovation and patients.
'In the next 12 month the company is looking
progressing some new indications for
Humira and has 20 molecules in the pipeline
which should see some new releases in the
coming 2--3 years.'
Ms O'Doherty said that unlike many
pharmaceutical companies AbbVie's current
portfolio of products is 'patent protected'
with nothing due to come off patent in the
near future which is an unusual position for a
pharmaceutical company to be in.
A statement announcing the launch of
the new company said that, 'A global
enterprise that serves patients in more than
170 countries, AbbVie launches with an
estimated $18 billion in annual revenues and
a strong commitment to creating shareholder
value through long-term growth potential
and the continuation of the company's
history of shareholder dividends'.
It said as well as a pipeline of more than
20 mid- to late-stage clinical programs
long-term growth will be fueled by new
discoveries to address diseases including
Hepatitis C, rheumatoid arthritis, psoriasis,
multiple sclerosis, Alzheimer's disease,
Parkinson's disease, spondyloarthropathies,
multiple myeloma and endometriosis.
Over the last few years AbbVie [the part of
Abbott than has become AbbVie] has tripled
the number of new molecular entities in
The statement also emphasized the new
company's focus on patients saying:
'AbbVie is focused on developing specialty
pharmaceuticals that address complex,
unsolved health problems, particularly
chronic diseases, that now account for 75% of
all healthcare costs. By developing new
specialty treatments that improve patient
outcomes, AbbVie and its people are helping
to reduce the long-term health and economic
impact of these conditions'.
AbbVie emerges from
By Andrew Daniels
Links Archive Australian Pharmacist January 2013 Australian Pharmacist March 2013 Navigation Previous Page Next Page